苯达莫司汀联合利妥昔单抗与利妥昔单抗联合化疗治疗惰性非霍奇金淋巴瘤或套细胞淋巴瘤疗效和安全性的Meta分析

The Efficacy and Safety of Bendamustine Combined with Rituximab and Rituximab Chemotherapy in the Treatment of Indolent Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma. A Meta Analysis

目的通过meta分析探讨苯达莫司汀联合利妥昔单抗与利妥昔单抗联合化疗治疗惰性非霍奇金淋巴瘤或套细胞淋巴瘤的疗效和安全性,从而为惰性非霍奇金淋巴瘤或套细胞淋巴瘤的治疗提供最佳的选择。方法采用Cochrane系统评价方法,计算机检索所有与利妥昔单抗、苯达莫司汀治疗惰性非霍奇金淋巴瘤或套细胞淋巴瘤的随机对照试验(RCT),评价纳入研究的方法学质量并进行资料提取后,采用Stata MP14.0软件进行Meta分析。结果共有2篇随机对照研究和1篇回顾性研究纳入meta分析中。利妥昔单抗联合苯达莫司汀比起利妥昔单抗联合化疗有着更低的毒性反应,差异有统计学意义,尤其在Ⅲ~Ⅳ级血液相关中性粒细胞减少(RR=0.58,95%CI=0.48~0.70,P<0.001)。结论meta分析结果表明利妥昔单抗联合苯达莫司汀比起利妥昔单抗联合化疗在治疗惰性非霍奇金淋巴瘤或套细胞淋巴瘤方面有着更好的毒性耐受,但目前没有足够的证据证明在无进展生存期和完全缓解率方面两者存在差异。

OBJECTIVE To investigate the efficacy and safety of bendamustine combined with rituximab and rituximab in the treatment of inert non-Hodgkin＇ s lymphoma or mantle cell lymphoma by meta-analysis,which is a study of inert non-Hodgkin＇s lymphoma or the treatment of cell lymphoma to provide the best choice. METHODS A randomized controlled trial（ RCT） of rituximab and bendamustine in the treatment of inert non-Hodgkin＇s lymphoma or mantle cell lymphoma was performed by Cochrane systematic review. The methodological quality of the included studies was evaluated and the data were extracted,using Stata MP 14. 0 software for meta-analysis. RESULTS A total of two randomized controlled studies and one retrospective study were included in the meta-analysis. Rituximab combined with bendamustine has a lower toxicity than rituximab in combination with chemotherapy,with statistically significant differences,especially in blood-related neutrophils at stage Ⅲ to Ⅳ（ RR = 0. 58,95% CI = 0. 48 to 0. 70,P〈0. 001）. CONCLUSION Meta analysis showed that rituximab combined with bendamustine is better tolerated than rituximab in the treatment of inert non-Hodgkin＇s lymphoma or mantle cell lymphoma,but there is currently insufficient evidence There is a difference between progression-free survival and complete remission.